Systemic Anti-Cancer Therapy Regimen Library
BR Metastatic - fulvestrant
Treatment Overview
Cycle 1 - 28 days
Cycle 2 (and all further cycles) - 28 days
Cycle details
Cycle 1 - 28 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| fulvestrant | 500 mg | intramuscular injection | 1, 15 |
Cycle 2 (and all further cycles) - 28 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| fulvestrant | 500 mg | intramuscular injection | 1 |
Full details
Cycle 1 - 28 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| fulvestrant | 500 mg | intramuscular injection |
Instructions:
500 mg dose should be administered as one 250 mg injection (slowly over 1–2 minutes) into each buttock (gluteal area). Dorsogluteal injection site should be used with care due to proximity to underlying sciatic nerve (increased risk of sciatica, neuralgia and peripheral neuropathy). |
Day: 15
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| fulvestrant | 500 mg | intramuscular injection |
Instructions:
500 mg dose should be administered as one 250 mg injection (slowly over 1–2 minutes) into each buttock (gluteal area). Dorsogluteal injection site should be used with care due to proximity to underlying sciatic nerve (increased risk of sciatica, neuralgia and peripheral neuropathy). |
Cycle 2 (and all further cycles) - 28 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| fulvestrant | 500 mg | intramuscular injection |
Instructions:
500 mg dose should be administered as one 250 mg injection (slowly over 1–2 minutes) into each buttock (gluteal area). Dorsogluteal injection site should be used with care due to proximity to underlying sciatic nerve (increased risk of sciatica, neuralgia and peripheral neuropathy). |
Supportive Care Factors
No supportive care factors specified
References
4. AstraZeneca. Faslodex New Zealand Data Sheet 16 July 2020. https://www.medsafe.govt.nz/profs/datasheet/f/faslodexinj.pdf (Accessed 27 April 2021)
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.